Document |
Document Title |
WO/2018/178142A1 |
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...
|
WO/2018/172133A1 |
Compounds of formula (I), wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to t...
|
WO/2018/172026A1 |
The invention relates to a process for synthesizing an aqueous N,N-dimethyl glucamine solution, characterized in that a formaldehyde solution is metered into an N-methyl glucamine solution in the presence of a metal catalyst at hydrogen ...
|
WO/2018/172025A1 |
The invention relates to a method for preparing aqueous solutions of N,N-dimethylglucamine, characterized by first preparing an adduct of N-methylglucamine and formaldehyde in water at temperatures of between 15°C and 40°C, and subsequ...
|
WO/2018/148113A1 |
The present invention is directed to 13C and/or 2H isotope enhanced ambroxol ("isotope enhanced ambroxol") and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditi...
|
WO/2018/143923A1 |
The present disclosure is drawn to an amine synergist including a tertiary benzylamine with a substituted benzene ring attached to a tertiary amine. The tertiary amine can be modified with multiple water soluble groups.
|
WO/2018/135506A1 |
The purpose of the present invention is to provide a ruthenium complex which is capable of serving as a reduction catalyst that is applicable to an industrial production. According to the present invention, ketones, aldehydes, esters or ...
|
WO/2018/129609A1 |
Compounds of formula (II) are useful in modulating voltage-gated sodium channel activity. Their preparation and use for reducing the severity of convulsant activity in a subject, for example in the treatment of epilepsy, is presented.
|
WO/2018/127806A1 |
The present invention provides a process for preparation of isoproterenol hydrochloride (1a) comprising catalytic hydrogenation of 3',4'-dihydroxy-2-(isopropylamino)-acetophenone hydrochloride (5a) in presence of an ion exchange resin, t...
|
WO/2018/129230A1 |
Synthetic methods for the preparation of ligands and metal-ligand complexes are disclosed.
|
WO/2018/126040A1 |
The present invention is generally directed to crystalline forms of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-me
thyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcy
clohexanol and processes for their preparation.
|
WO/2018/124148A1 |
The purpose of the present invention relates to providing a novel glyceric acid ester which can be produced at a high yield and for which use as a synthesis intermediate can be expected, and a method for producing same. The purpose of th...
|
WO/2018/124149A1 |
The purpose of the present invention is to provide a method for producing glyceric acid ester that enables easy, high-yield production and makes it easy to reuse pyridines that are used for a reaction. Provided is a method for producing ...
|
WO/2018/124147A1 |
The present invention relates to a method for manufacturing 1,3-dioxane-5-ones by a short and simple method from raw materials that can be obtained easily and inexpensively, using 1,3-dioxane, which is a mixture with 1,3-dioxalans, as a ...
|
WO/2018/113581A1 |
Disclosed are a conjugate of dezocine and polyethylene glycol and a pharmaceutical composition thereof, wherein same have better pharmacokinetical properties and a high drug absorption degree, can decrease the side effects of drugs, and ...
|
WO/2018/119263A1 |
Disclosed are compounds of Formula (I'), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing o...
|
WO/2018/108797A1 |
The invention relates primarily to a method for producing L-glufosinate or the salts thereof using ephedrine, in particular for producing L-glufosinate or the salts thereof by (dynamic kinetic) resolution of racemates. The invention also...
|
WO/2018/108888A1 |
The invention pertains to a process for preparing hydroxyethyl ethylene amines and/or ethylene urea derivatives thereof comprising the step of reacting monoethylene glycol with an amine-functional compound comprising at least two -NH- un...
|
WO/2018/108794A1 |
The invention relates to a method for producing D-glufosinate or salts thereof using ephedrine, in particular for producing D-glufosinate or salts thereof by (dynamic kinetic) resolution of racemates. The invention also relates to certai...
|
WO/2018/108698A1 |
The invention relates to a method for producing ethanolamines and/or ethyleneamines in the gas phase by reacting ethylene glycol with ammonia in the presence of an amination catalyst. The method is characterized in that the amination cat...
|
WO/2018/104176A1 |
The invention relates to a method for producing farnesyl amines by reacting ß-farnesene with one or more amines in the presence of a transition metal catalyst of the10th subgroup, at a temperature in the region of between 60 - 150 °C. (I)
|
WO/2018/090982A1 |
Provided are a benzodicycloalkane derivative, and a preparation method and use thereof. In particular, provided is a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, a preparation method th...
|
WO/2018/067685A1 |
Described herein are compounds that disrupt the interaction between Fbxo48 and phosphorylated-AMPK.
|
WO/2018/064476A1 |
Crystalline 2-hydroxy-N,N-dimethylethanaminium 1 -(2-(5-(tert-butyl) -thiophene-2-carboxamido)-3-(4-(5-(4'-ethyl-[1,1'-bi(cyclohe
xan)]-3- en-4-yl)pyrimidin-2-yl)phenyl)propanoyl)azetidine-3-carboxyl
ate salt, and methods related to synt...
|
WO/2018/048932A1 |
Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) or nonalcoholic steato...
|
WO/2018/044982A1 |
A process for preparing a silver-containing catalyst for the selective oxidation of ethylene to ethylene oxide including the steps of: (a) providing a multimodal support, (b) preparing an impregnation solution comprising a silver compone...
|
WO/2018/028679A1 |
A post-processing method for a Mirabegron intermediate, comprising the following steps: with a Mirabegron carbonyl of formula I serving as a reaction raw material, the carbonyl therein is reduced via a reduction reaction under the effect...
|
WO/2018/022871A1 |
Embodiments are directed to terphenyl ligands and metal complex formed therefrom, wherein the metal complexes are used as procatalyst in polyolefin polymerization and comprise the following structure:
|
WO/2018/009720A1 |
Methods and compounds for use in promoting survival of at least one eukaryotic cell, wherein the compounds are effective as gamma-ketoaldehyde scavengers.
|
WO/2018/000098A1 |
A method of treating an inflammatory myopathy includes topically administering to the skin of an individual with the inflammatory myopathy a composition comprising R-salbutamol, a physiologically acceptable derivative thereof, or a pharm...
|
WO/2018/004945A1 |
A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO by providing a composition comprising a compound set forth in Formula (I):
|
WO/2017/218886A1 |
The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.
|
WO/2017/214680A1 |
The present invention relates to new multi-functional compounds that are useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, to the preparation of the compounds, and to compositions including the compounds...
|
WO/2017/215592A1 |
The present disclosure provides co-crystals of a lithium benzoatecompound and a co-former compound of Formula (I). Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a ...
|
WO/2017/212007A1 |
Compositions for nucleic acid delivery are provided which comprise a relatively low amount a permanently cationic lipid or lipidoid, such as a lipid comprising a quaternary ammonium group. The compositions are suitable for the delivery o...
|
WO/2017/214334A1 |
Disclosed herein are lignin-derived ionic liquids and methods for preparing them. The methods include forming a reaction mixture comprising a lignin-derived starting material, a carbonyl compound, and an amine; maintaining the reaction m...
|
WO/2017/212009A1 |
A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of...
|
WO/2017/207839A1 |
The invention relates to a method for obtaining β-amino alcohols, in which the following steps are performed using amines and a diol/water mixture: adding a catalytic mixture to the starting amine; next, adding the diol/water mixture; s...
|
WO/2017/206692A1 |
An organic amine salt compound having the general formula (I): An-[Bm+]p. In the formula, An- is anions having -n valence serving as CO2 donors, wherein n = 1, 2, or 3; Bm+ is or contains: ammonium ions and/or organic amine B cations; m ...
|
WO/2017/206693A1 |
An organic amine salt compound having the general formula (I): An-[Bm+]p. In the formula, An- is anions having -n valence serving as CO2 donors, wherein n = 1, 2, or 3; Bm+ is or contains: ammonium ions, hydrazine ions and/or organic ami...
|
WO/2017/209235A1 |
The present invention addresses the problem of providing a low-cost and highly-safe method for producing a polycyclic aromatic aminophenol compound in a small number of steps. The method for producing a polycyclic aromatic aminophenol co...
|
WO/2017/197014A2 |
Compositions comprising a polymeric dye and a cyclodextrin are provided. Methods associated with preparation and use of such compounds, for example in methods for detection of any analyte molecule, are also provided.
|
WO/2017/193913A1 |
Provided are a fosaprepitant phosphate intermediate (IV) preparation method, a fosaprepitant phosphate intermediate (IV-A) and a method (AA) for preparing fosaprepitant dimeglumine by using the intermediate (IV-A). IV: R1 and R2 are inde...
|
WO/2017/185261A1 |
The present invention relates to the technical field of medicine, and provides mosapride active metabolites (R)-N-[2-hydroxy-3-(4-fluorobenzyl)amino]propyl-5-chloro-4-a
mino-2-ethoxy benzamide (levo isomer) and (S)-N-[2-hydroxy-3-(4-fluo...
|
WO/2017/182438A1 |
The present invention relates to tapentadol phosphate in crystalline form and to a process for producing tapentadol phosphate in crystalline form. Further,the present invention relates to a composition comprising crystalline tapentadol p...
|
WO/2017/177065A2 |
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Meth...
|
WO/2017/173355A1 |
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Meth...
|
WO/2017/173348A1 |
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, L5, A, M, m and n are as defined herei...
|
WO/2017/159814A1 |
The present invention provides a method for producing ethanolamines whereby it is possible to keep the yield of dialkanolamines low (for example, less than 30% by weight). This method for producing alkanolamines involves reacting an alky...
|
WO/2017/152083A1 |
Processes are described for the preparation of F-benzoxazinorifamycin I: and intermediates for conjugation with an antibody.
|